Fig. 3.
Fig. 3. A schematic comparison of F.XIa and HNE cleavage of human F.IX. Human F.IX is composed of a light chain (residues 1-145), an activation peptide (residues 146-180), and a heavy chain (residues 181-415). The light chain is composed of a γ-carboxylglutamyl-(GLA) containing domain, two domains with homology to human epidermal growth factor (EGF), and a linker (L) domain.10 The activation peptide (AP) is cleaved upon F.IX activation by F.XIa. The catalytic domain (CD) contains the active site formed by the triad of Asp269, His221, and Ser365residues. The results of the NH2-terminal sequencing indicate that HNE inactivates human F.IX coagulant activity after cleaving at Thr140, Thr144, Ile164, Thr172, and Val181. Human F.IX is shown with the position of the cleavage sites for either F.XIa (top) or HNE (bottom).

A schematic comparison of F.XIa and HNE cleavage of human F.IX. Human F.IX is composed of a light chain (residues 1-145), an activation peptide (residues 146-180), and a heavy chain (residues 181-415). The light chain is composed of a γ-carboxylglutamyl-(GLA) containing domain, two domains with homology to human epidermal growth factor (EGF), and a linker (L) domain.10 The activation peptide (AP) is cleaved upon F.IX activation by F.XIa. The catalytic domain (CD) contains the active site formed by the triad of Asp269, His221, and Ser365residues. The results of the NH2-terminal sequencing indicate that HNE inactivates human F.IX coagulant activity after cleaving at Thr140, Thr144, Ile164, Thr172, and Val181. Human F.IX is shown with the position of the cleavage sites for either F.XIa (top) or HNE (bottom).

Close Modal

or Create an Account

Close Modal
Close Modal